Wells Fargo & Company Issues Positive Forecast for Medline (NASDAQ:MDLN) Stock Price

Medline (NASDAQ:MDLN) had its price target boosted by analysts at Wells Fargo & Company from $42.00 to $47.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential downside of 2.83% from the company’s current price.

A number of other equities research analysts have also weighed in on MDLN. Mizuho initiated coverage on shares of Medline in a report on Monday, January 12th. They set an “outperform” rating and a $48.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Medline in a research note on Monday, January 12th. They set a “buy” rating and a $50.00 price target for the company. Bank of America assumed coverage on Medline in a research report on Monday, January 12th. They set a “buy” rating and a $50.00 price target on the stock. Wolfe Research started coverage on Medline in a research note on Monday, January 12th. They set an “outperform” rating and a $47.00 price target on the stock. Finally, BNP Paribas Exane began coverage on shares of Medline in a report on Monday, January 12th. They set a “neutral” rating and a $38.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $50.35.

Medline Stock Performance

NASDAQ:MDLN traded down $0.52 during midday trading on Friday, hitting $48.37. 844,446 shares of the company traded hands, compared to its average volume of 3,304,363. The firm has a fifty day moving average price of $44.40. Medline has a 12-month low of $34.89 and a 12-month high of $50.88.

Medline (NASDAQ:MDLN) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The business had revenue of $7.79 billion for the quarter, compared to analyst estimates of $7.52 billion. The company’s revenue was up 14.8% on a year-over-year basis.

Insider Buying and Selling at Medline

In other news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the company’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the transaction, the insider directly owned 4,806,160 shares of the company’s stock, valued at approximately $136,350,759.20. This represents a 55.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Charles N. Mills acquired 2,579,310 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were acquired at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the acquisition, the director owned 2,441,379 shares in the company, valued at approximately $70,799,991. The trade was a -1,870.00% increase in their position. The SEC filing for this purchase provides additional information.

Institutional Trading of Medline

A number of institutional investors have recently bought and sold shares of MDLN. Truist Financial Corp purchased a new stake in shares of Medline during the fourth quarter valued at $240,000. Entrust Financial LLC purchased a new position in Medline in the 4th quarter worth $26,000. Charles Schwab Investment Management Inc. acquired a new stake in Medline during the 4th quarter worth about $32,762,000. Comerica Bank purchased a new stake in Medline during the 4th quarter valued at about $204,000. Finally, Mitsubishi UFJ Trust & Banking Corp acquired a new position in shares of Medline in the fourth quarter valued at about $4,593,000.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Multiple brokerages raised price targets and turned more constructive after the quarter — Citi raised its target to $60 (buy), UBS to $57 (buy), BMO to $54 (outperform) and RBC to $53 (outperform), signaling analyst confidence in Medline’s growth outlook. Analysts Boost Their Forecasts Following Q4 Results
• Positive Sentiment: Revenue beat: Q4 sales were $7.79B vs. consensus ~$7.52B, up ~14.8% year-over-year — supports top-line momentum and was called “record sales” in earnings highlights. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: The full Q4 earnings call transcript and company commentary are available for detail on margins, margin drivers and capital/ESOP plans — useful for assessing whether the EPS miss is one-off or structural. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Independent coverage provides quick snapshots of results and context on product/segment performance — use these to cross-check management’s narrative. Q4 Earnings Snapshot
• Negative Sentiment: EPS miss: reported EPS was ($0.01) vs. consensus $0.24 — the earnings shortfall is the primary near-term negative catalyst and was cited as the reason for the share gap down. Shares Gap Down Following Weak Earnings
• Negative Sentiment: IPO/ESOP scrutiny: the company’s public filing and ESOP plans are under increased public scrutiny, raising questions about governance, dilution and guidance clarity as Medline transitions to the public market. IPO Opens Public Scrutiny On Growth Guidance And ESOP Plans
• Negative Sentiment: Coverage noting “shortcomings”: some write-ups highlight that, despite growth, the quarter revealed weaknesses (profitability/mix) that need addressing — a reminder that revenue strength hasn’t fully translated into EPS beat. Reports Growth Despite Earnings Shortcomings

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.